Boston Scientific Co. (NYSE:BSX) Shares Sold by Symmetry Partners LLC

Symmetry Partners LLC trimmed its stake in shares of Boston Scientific Co. (NYSE:BSX) by 10.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,826 shares of the medical equipment provider’s stock after selling 683 shares during the period. Symmetry Partners LLC’s holdings in Boston Scientific were worth $237,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of BSX. Nuveen Asset Management LLC grew its holdings in Boston Scientific by 5,664.6% during the second quarter. Nuveen Asset Management LLC now owns 8,797,616 shares of the medical equipment provider’s stock worth $378,122,000 after acquiring an additional 8,645,002 shares during the period. Viking Global Investors LP grew its holdings in Boston Scientific by 185.5% during the second quarter. Viking Global Investors LP now owns 9,195,192 shares of the medical equipment provider’s stock worth $395,209,000 after acquiring an additional 5,974,823 shares during the period. Marshall Wace LLP grew its holdings in Boston Scientific by 116.3% during the second quarter. Marshall Wace LLP now owns 9,545,382 shares of the medical equipment provider’s stock worth $410,261,000 after acquiring an additional 5,131,591 shares during the period. Invesco Ltd. grew its holdings in Boston Scientific by 43.2% during the second quarter. Invesco Ltd. now owns 12,320,389 shares of the medical equipment provider’s stock worth $529,530,000 after acquiring an additional 3,714,624 shares during the period. Finally, Vontobel Asset Management Inc. grew its holdings in Boston Scientific by 245.4% during the second quarter. Vontobel Asset Management Inc. now owns 4,873,792 shares of the medical equipment provider’s stock worth $215,565,000 after acquiring an additional 3,462,586 shares during the period. 91.64% of the stock is currently owned by hedge funds and other institutional investors.

BSX has been the topic of several analyst reports. Guggenheim set a $53.00 target price on Boston Scientific and gave the stock a “buy” rating in a report on Friday, October 25th. Barclays reaffirmed an “overweight” rating and set a $48.00 target price on shares of Boston Scientific in a report on Tuesday, September 3rd. JPMorgan Chase & Co. initiated coverage on Boston Scientific in a research report on Thursday, September 5th. They set an “overweight” rating on the stock. Needham & Company LLC reiterated a “buy” rating and set a $53.00 price target on shares of Boston Scientific in a research report on Wednesday, October 23rd. Finally, Stifel Nicolaus set a $47.00 price target on Boston Scientific and gave the stock a “buy” rating in a research report on Friday, September 6th. Two investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Boston Scientific has an average rating of “Buy” and an average target price of $47.07.

In other news, SVP John Bradley Sorenson sold 6,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $42.79, for a total value of $256,740.00. Following the transaction, the senior vice president now owns 42,385 shares in the company, valued at $1,813,654.15. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP David A. Pierce sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $42.50, for a total value of $212,500.00. Following the completion of the transaction, the executive vice president now owns 29,201 shares in the company, valued at approximately $1,241,042.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 101,072 shares of company stock worth $4,188,092. Company insiders own 0.66% of the company’s stock.

BSX stock traded down $0.21 during mid-day trading on Friday, reaching $40.51. 3,199,353 shares of the company’s stock were exchanged, compared to its average volume of 7,209,796. The company has a market cap of $56.54 billion, a price-to-earnings ratio of 27.56, a price-to-earnings-growth ratio of 2.27 and a beta of 0.76. The stock’s 50 day moving average is $40.34 and its 200 day moving average is $40.64. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.31 and a quick ratio of 1.04. Boston Scientific Co. has a 12-month low of $31.56 and a 12-month high of $43.84.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.01. The company had revenue of $2.71 billion for the quarter, compared to the consensus estimate of $2.68 billion. Boston Scientific had a return on equity of 23.47% and a net margin of 10.49%. Boston Scientific’s revenue for the quarter was up 13.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.35 earnings per share. On average, research analysts forecast that Boston Scientific Co. will post 1.56 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Featured Story: What is the definition of market timing?

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.